comparemela.com

Page 3 - Biogeneric News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center | Proteins and Peptides

Hits: 1900 - Seed investment by Swanbridge Capital and Van Herk Ventures with support from Health~Holland ROTTERDAM, The Netherlands I February 8, 2021 I Pan Cancer T B.V., a biotech spin-off from the Erasmus Medical Center founded by Prof. Dr. Reno Debets (CSO) and Dr. Dora Hammerl (VP R&D), announces the closing of a seed investment and start of operations. Together with Katrien Reynders-Frederix (CEO), the team is committed to the discovery and development of novel TCR therapies against solid tumors such as triple negative breast cancer, bladder cancer, lung cancer, and glioma. Seed investors are Swanbridge Capital and Van Herk Ventures, and the Company is further awarded a Health~Holland grant for a public-private-partnership with Erasmus Medical Center.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.